Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

[1]  N. Harbeck,et al.  Personalized treatment of early-stage breast cancer: present concepts and future directions. , 2010, Cancer treatment reviews.

[2]  L. Kiesel,et al.  Neue Konzepte in der zielgerichteten systemischen Therapie des Mammakarzinoms , 2010 .

[3]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Hortobagyi,et al.  Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Rodenhuis,et al.  The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy , 2010, Annals of Surgical Oncology.

[6]  D. Dabbs,et al.  Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy , 2010, Cancer.

[7]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[8]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[9]  J. Cuzick,et al.  Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. , 2009 .

[10]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[11]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Keshtgar,et al.  31st annual san antonio breast cancer symposium , 2009 .

[13]  P. Fasching,et al.  Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. , 2009 .

[14]  P. Sánchez‐Rovira,et al.  Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[15]  G. Hortobagyi,et al.  Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[17]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Hortobagyi,et al.  HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer , 2008, Breast Cancer Research and Treatment.

[19]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[21]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[22]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[23]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Kaufmann,et al.  Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie , 1994 .

[25]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[26]  P. Fasching,et al.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.

[27]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[28]  H. Junkermann,et al.  [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. , 1994, Geburtshilfe und Frauenheilkunde.

[29]  B. Lausen,et al.  Computational Statistics and Data Analysis Bootstrap Estimated True and False Positive Rates and Roc Curve , 2022 .